Quantcast
Simple Blood Test Could Be Used As Tool For Early Cancer

Simple Blood Test Could Be Used As Tool For Early Cancer Diagnosis

University of Bristol Hypercalcaemia is the most common metabolic disorder associated with cancer, occurring in 10 to 20 percent of people with cancer. While its connection to cancer is well known, this study has, for the first time, shown that...

Latest Prostate cancer Stories

2014-09-30 23:25:03

Hair Club for Men and Women Offers Free Hair & Scalp Analysis to Uncover Hair and Scalp Condition Boca Raton, Florida (PRWEB) September 30, 2014 In 2011, there were an estimated 2,707,821 men living with prostate cancer in the United States, according to the National Cancer Institute. Prostate cancer is the second most common cancer among men in the US, and now, new research is suggesting that there may be a correlation between this prevalent cancer and a certain pattern of hair...

2014-09-30 16:28:27

FLINT, Mich., Sept. 30, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that XTANDI(®) has been granted an expanded approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (CRPC). The new indication allows for the use of XTANDI in patients who have not received chemotherapy. XTANDI is an oral, once-daily androgen receptor inhibitor capsule now available for patients in...

2014-09-30 08:32:22

Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing...

2014-09-30 08:30:47

Prostate Cancer Canada grant aims to accelerate pace of discovery of novel therapies TORONTO, Sept. 30, 2014 /CNW/ - Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada just awarded a Translation Acceleration Grant (TAG) to a team led by Dr. Paul Rennie of the Vancouver Prostate Centre and the...

2014-09-29 23:08:39

This new genetic-based imaging technique is able to detect cancerous cells through expression of a gene called AEG-1. BETHESDA, MD (PRWEB) September 29, 2014 The very first sensitive and specific molecular imaging technique to detect bone metastases was recently developed by NFCR-funded scientist Paul B. Fisher, M.Ph., Ph.D., at the Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine in collaboration with Martin G. Pomper, M.D., Ph.D., at the...

2014-09-29 16:25:57

Additional Tests to Demonstrate the Importance of Utilizing Multiple Biological Pathways to Provide Patients, Physicians with Confidence to Make Educated Treatment Decisions CAMBRIDGE, Mass., Sept. 29, 2014 /PRNewswire/ -- Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA(®) PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. These tests...

2014-09-29 16:24:13

TORONTO, Sept. 29, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY -- Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada will be funding breakthrough research into a new generation of drugs that used alone or in combination with other therapies will...

2014-09-29 12:28:40

ALBANY, New York, September 29, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market [Technologies: Tumor Cell Enrichment (Filtration, Centrifugation and Immunological & Immunomagnetic Methods) & Tumor Cell Detection (Molecular Methods and Optical Methods) and Applications: Prostate Cancer, Breast Cancer, Colorectal Cancer and Others] - Global Industry...

2014-09-29 08:32:13

SYDNEY, Sept. 29, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV that was broadcast on Saturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview concerned the Company's efforts in bringing its drug candidate, Trilexium, into the clinic in Australia for the treatment of primary brain cancers such as glioblastoma multiforme. The...

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related